Skip to main content

We've saved some files called cookies on your device. These cookies are:

  • essential for the site to work
  • to help improve our website by collecting and reporting information on how you use it

We would also like to save some cookies to help tailor communications.

BETA
You're viewing an updated version of this service - your feedback will help us to improve it.

03 Contract Award Notice - Incomplete Procedure

Drug Development Framework

  • First published: 19 January 2021
  • Last modified: 19 January 2021
  • Version: N/A
  •  

  • This file may not be fully accessible.

  •  

Information icon

The buyer is not using this website to administer the notice.

To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Contents

Summary

OCID:
ocds-kuma6s-101107
Published by:
Cardiff University
Authority ID:
AA0258
Publication date:
19 January 2021
Deadline date:
-
Notice type:
03 Contract Award Notice - Incomplete Procedure
Has documents:
No
Has SPD:
No
Has Carbon Reduction Plan:
N/A

Abstract

Cardiff University are ranked 2nd nationally for the impact of their research and are among the top five universities in the UK for research excellence. Cardiff University has a thriving and innovative research culture, with research that has real impact and makes a positive difference to the world. As part of this, the University is translating fundamental discoveries in disease processes to develop new medicines to meet unmet clinical needs. Cardiff University is looking for companies with an innovative outlook and recognised expertise in supporting drug-discovery projects from early screening (electrophysiology and in vitro DMPK) to delivering de-risked novel molecules to clinical trials. Successful companies will be committed to the principles of the NC3Rs and will add value to our work by providing high-quality data for informing the drug-discovery pipeline. CPV: 73111000, 73111000, 73111000, 73111000, 73111000.

Full notice text

Contract award notice

Results of the procurement procedure

Section I: Contracting entity

I.1) Name and addresses

Cardiff University

Procurement Services, McKenzie House, 30-36 Newport Road

Cardiff

CF24 0DE

UK

Telephone: +44 2920879648

E-mail: Buyline@cardiff.ac.uk

NUTS: UKL

Internet address(es)

Main address: http://www.cardiff.ac.uk/business/why-work-with-us/for-suppliers

Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0258

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Education

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Drug Development Framework

Reference number: CU258

II.1.2) Main CPV code

73111000

 

II.1.3) Type of contract

Services

II.1.4) Short description

Cardiff University are ranked 2nd nationally for the impact of their research and are among the top five universities in the UK for research excellence. Cardiff University has a thriving and innovative research culture, with research that has real impact and makes a positive difference to the world. As part of this, the University is translating fundamental discoveries in disease processes to develop new medicines to meet unmet clinical needs.

Cardiff University is looking for companies with an innovative outlook and recognised expertise in supporting drug-discovery projects from early screening (electrophysiology and in vitro DMPK) to delivering de-risked novel molecules to clinical trials. Successful companies will be committed to the principles of the NC3Rs and will add value to our work by providing high-quality data for informing the drug-discovery pipeline.

II.1.6) Information about lots

This contract is divided into lots: Yes

II.2) Description

Lot No: 1

II.2.1) Title

Electrophysiology Services

II.2.2) Additional CPV code(s)

73111000

II.2.3) Place of performance

NUTS code:

UKL22

II.2.4) Description of the procurement

We require providers for electrophysiology services relevant to neuroscience drug development.

Currently we require validated ion channel assays for GABAA and NMDA modulators, on an automated electrophysiology platform, with QC and report generation.

In the near future, it is likely we will require a range of other ion channel assays, as well as manual patch clamp services. We may also want to purchase ion channel expressing cell lines (under a MTA).

II.2.5) Award criteria

Quality criterion: as per procurement docs / Weighting: 100

Price / Weighting:  0

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

Lot No: 2

II.2.1) Title

In-vivo assays

II.2.2) Additional CPV code(s)

73111000

II.2.3) Place of performance

NUTS code:

UKL22

II.2.4) Description of the procurement

We require providers for in-vivo assays, most usually with oral administration. We currently require reliable assays for pro-cognitive and anxiolytic effects. In the future, we may require assays to demonstrate other drug modulated effects, such as, but not limited to, an anti-depressive effect.

II.2.5) Award criteria

Quality criterion: as per procurement docs / Weighting: 100

Price / Weighting:  0

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

Lot No: 3

II.2.1) Title

In-vitro drug metabolism (ADME-Tox) services

II.2.2) Additional CPV code(s)

73111000

II.2.3) Place of performance

NUTS code:

UKL22

II.2.4) Description of the procurement

We require providers of in-vitro drug metabolism (ADME-Tox) services as part of our drug development pipeline. This includes, but is not limited to, measures of metabolism, permeability and transporters, physicochemical properties, protein binding and toxicology.

II.2.5) Award criteria

Quality criterion: as per procurement docs / Weighting: 100

Price / Weighting:  0

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

Lot No: 4

II.2.1) Title

In-vivo pharmacokinetics (PK) and toxicology

II.2.2) Additional CPV code(s)

73111000

II.2.3) Place of performance

NUTS code:

UKL22

II.2.4) Description of the procurement

We require providers of in-vivo drug metabolism (ADME-Tox) services as part of our drug development pipeline.

II.2.5) Award criteria

Quality criterion: as per procurement docs / Weighting: 100

Price / Weighting:  0

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2020/S 074-177464

Section V: Award of contract

Lot No: 1

Contract No: CU258

Title: Electrophysiology Services

A contract/lot is awarded: No

V.1 Information on non-award

The contract/lot is not awarded

Other reasons (discontinuation of procedure)

Section V: Award of contract

Lot No: 2

Contract No: CU258

Title: In-vivo assays

A contract/lot is awarded: No

V.1 Information on non-award

The contract/lot is not awarded

Other reasons (discontinuation of procedure)

Section V: Award of contract

Lot No: 3

Contract No: CU258

Title: In-vitro drug metabolism (ADME-Tox) services

A contract/lot is awarded: No

V.1 Information on non-award

The contract/lot is not awarded

Other reasons (discontinuation of procedure)

Section V: Award of contract

Lot No: 4

Contract No: CU258

Title: In-vivo pharmacokinetics (PK) and toxicology

A contract/lot is awarded: No

V.1 Information on non-award

The contract/lot is not awarded

Other reasons (discontinuation of procedure)

Section VI: Complementary information

VI.3) Additional information

Bidders will need to create an account via In-Tend (https://in-tendhost.co.uk/cardiffuniversity/aspx/Home) in order to view the tender documents.

(WA Ref:107445)

VI.4) Procedures for review

VI.4.1) Review body

High Court

Royal Courts of Justice, The Strand

London

WC2A 2LL

UK

Telephone: +44 2079477501

VI.5) Date of dispatch of this notice

19/01/2021

Coding

Commodity categories

ID Title Parent category
73111000 Research laboratory services Research services

Delivery locations

ID Description
1022 Cardiff and Vale of Glamorgan

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID Description
There are no alert restrictions for this notice.

Document family

Notice details
Publication date:
15 April 2020
Deadline date:
17 January 2021 00:00
Notice type:
02 Contract Notice
Authority name:
Cardiff University
Publication date:
09 June 2020
Notice type:
14 Corrigendum
Authority name:
Cardiff University
Publication date:
19 January 2021
Notice type:
03 Contract Award Notice - Incomplete Procedure
Authority name:
Cardiff University

About the buyer

Main contact:
Buyline@cardiff.ac.uk
Admin contact:
N/a
Technical contact:
N/a
Other contact:
N/a

Further information

Date Details
No further information has been uploaded.

0800 222 9004

Lines are open 8:30am to 5pm Monday to Friday.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.